Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.

Abstract

The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients.LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients.LA was not associated with thrombotic complications.The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.

Keywords: Anti-β2-glycoprotein-I; Anticardiolipin; COVID-19; Lupus anticoagulant; Thrombosis.

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Antiphospholipid / blood*
  • Betacoronavirus / isolation & purification
  • Coronavirus Infections / blood*
  • Coronavirus Infections / complications
  • Critical Illness / epidemiology
  • Humans
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / blood*
  • Pneumonia, Viral / complications
  • Prospective Studies
  • Thrombosis / blood*
  • Thrombosis / etiology

Substances

  • Antibodies, Antiphospholipid

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2